PB 100
Latest Information Update: 10 Sep 2003
At a glance
- Originator Nonindustrial source
- Class Antineoplastics; Carbolines
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 13 Jun 2001 This compound is still in active development
- 13 Jun 2001 Preclinical development for Cancer in France (Unknown route)
- 10 Sep 1998 No-Development-Reported for Cancer in France (Unknown route)